ZT 辉瑞疫苗有效率只有29%?美国实验真造假吗?
- 主题发起人 Hard Worker
- 开始时间
TrumpEstate
初级会员
- 注册
- 2019-06-27
- 消息
- 836
- 荣誉分数
- 194
- 声望点数
- 53
这个不说明问题。是10个人打了疫苗有7个被感染，还是1万个人打了，或是100万个人打了疫苗？你的结论“也是很高的数字”让人摸不着头脑。打过疫苗以后，蒙特利尔一个中心7个人感染了病毒。 一个楼就感染了7个，即使第一针50%有效，也是很高的数字。
Résidants d’un CHSLD vaccinés et infectés | Une situation « prévisible », préviennent les experts
Même s’ils ont eu une première dose du vaccin contre la COVID-19 en décembre, sept résidants du CHSLD Maimonides ont reçu un diagnostic positif à l’infection dans le dernier mois. Une situation qui, tout en étant malheureuse, est aussi « prévisible », préviennent les experts en vaccination, qui...www.lapresse.ca
billwanhua
本站元老
- 注册
- 2005-07-07
- 消息
- 16,731
- 荣誉分数
- 5,494
- 声望点数
- 373
这个好像是个犹太人养老中心，一个大楼住的人不会很多。
所以，7个人感染对一个大楼来说，怎么讲都是很高的数字。
billwanhua
本站元老
- 注册
- 2005-07-07
- 消息
- 16,731
- 荣誉分数
- 5,494
- 声望点数
- 373
7 Maimonides residents who were vaccinated test positive for COVID-19 - Montreal | Globalnews.ca
"The recent COVID positive residents have all received their first dose of the COVID vaccine and were infected within the first 28 days after their first dose."
globalnews.ca
COVID-19 vaccine delayed for Maimonides Geriatric Centre residents in Montreal - Montreal | Globalnews.ca
The province has decided it's going to redirect those second doses and any vaccine they get in the next few weeks to as many people as possible.
globalnews.ca
“Please rest assured that this change will not affect your health or well-being. In fact, research has shown that the Pfizer vaccine achieves 90% effectiveness two weeks after the first dose has been administered. The second dose is a “booster” shot that enhances the already high level of protection,” Dr. Rosenberg wrote in a statement.
最后编辑:
打过疫苗以后，蒙特利尔一个中心7个人感染了病毒。 一个楼就感染了7个，即使第一针50%有效，也是很高的数字。Résidants d’un CHSLD vaccinés et infectés | Une situation « prévisible », préviennent les experts
Même s’ils ont eu une première dose du vaccin contre la COVID-19 en décembre, sept résidants du CHSLD Maimonides ont reçu un diagnostic positif à l’infection dans le dernier mois. Une situation qui, tout en étant malheureuse, est aussi « prévisible », préviennent les experts en vaccination, qui...
哈哈哈，美帝疫苗估计只有百分之一的有效，快去服用板蓝根
- 注册
- 2003-09-30
- 消息
- 79,632
- 荣誉分数
- 23,505
- 声望点数
- 1,373
你自己上网查新闻。
一个反对一切疫苗的疯子的疯话，“发表”在一个医学杂志的评论区，被一个坏人描绘成一个专家在一个顶级杂志发表的论文，去骗一群傻子，在华人媒体里流传。
billwanhua
本站元老
- 注册
- 2005-07-07
- 消息
- 16,731
- 荣誉分数
- 5,494
- 声望点数
- 373
hold your horse, 这个会是一个很好的疫苗实际效果案例。等等看这7个感染的人有没有转重症状或者死亡的，如果没有，说明疫苗还是比较好的， 老人院。
- 注册
- 2012-09-04
- 消息
- 64,494
- 荣誉分数
- 11,680
- 声望点数
- 1,373
19% or 95%? US expert challenges Pfizer vaccine’s efficacy, triggers debates in China
By Leng Shumei and Bai YunyiPublished: Jan 13, 2021 10:55 PM
An illustration shows vials of a COVID-19 vaccine and syringes with the logos of US pharmaceutical company Pfizer and German partner BioNTech. Photo: AFP
Questions raised by Peter Doshi, an assistant professor of pharmaceutical health services research at the University of Maryland School of Pharmacy, have triggered heated discussion on Chinese social media.
Doshi's opinion was disputed among Chinese vaccine experts interviewed by the Global Times. Many experts agreed that Pfizer should provide more raw data for peer review but said Doshi's methodology may be flawed.
Chinese experts also noted that disputes often arise from clinical trial data of COVID-19 vaccines, given the difference in participant groups and how different pharmaceutical companies define COVID-19 symptoms differently. They said that the efficacy rate of a vaccine should be evaluated in a more comprehensive manner, citing Sinovac as an example.
Sinovac vaccine received a 50.3-percent efficacy rate on Wednesday, based on phase III clinical trials in Brazil. But the figure was largely due to the fact that participants in Brazil are all medical workers with a very high infection risk, experts said.
Doshi on January 4 released an article on a blog platform under the UK pharmaceutical journal The BMJ, questioning Pfizer's efficacy rate.
Pfizer revealed that it discovered 170 PCR confirmed COVID-19 cases during the phase III clinical trials and 3,410 suspected cases in total.
However, if taking these suspected cases all as confirmed ones, the Pfizer vaccine's efficacy would be dramatically reduced to 19 percent. Even after omitting cases occurring within seven days of vaccination, which should include the majority of symptoms due to short-term vaccine reactogenicity, the efficacy rate remains as low as 29 percent, Doshi said in the article.
Doshi also questioned the standards of how Pfizer excluded cases and the influence of the use of medication on the vaccine's efficacy.
Doshi's comments triggered controversy on Chinese social media platforms, with some Chinese experts doubting Doshi's counting method for efficacy as he takes all participants showing symptoms to be confirmed COVID-19 cases, even if PRC tests show negative results.
"The PRC test is of very high sensitivity, 98.6 percent in the last year. But its sensitivity could be only 5 percent under Doshi's counting method," Zhuang Shilihe, a Guangzhou-based vaccine doctor, told the Global Times on Wednesday.
Zhuang noted that Doshi's doubts may be related to the anti-vaccine movement in the US, noting that Doshi has previously criticized other vaccines like the flu vaccines.
A Beijing-based vaccine expert who required anonymity expressed distrust of Pfizer's efficacy, but he did not directly comment on Doshi's doubts.
Despite different opinions on the Pfizer vaccine's efficacy, both experts said that Pfizer should reveal the raw data for peer review to better analyze the vaccine, so as to exclude the influence of any environmental or other elements on the efficacy.
By Leng Shumei and Bai YunyiPublished: Jan 13, 2021 10:55 PM
An illustration shows vials of a COVID-19 vaccine and syringes with the logos of US pharmaceutical company Pfizer and German partner BioNTech. Photo: AFP
Questions raised by Peter Doshi, an assistant professor of pharmaceutical health services research at the University of Maryland School of Pharmacy, have triggered heated discussion on Chinese social media.
Doshi's opinion was disputed among Chinese vaccine experts interviewed by the Global Times. Many experts agreed that Pfizer should provide more raw data for peer review but said Doshi's methodology may be flawed.
Chinese experts also noted that disputes often arise from clinical trial data of COVID-19 vaccines, given the difference in participant groups and how different pharmaceutical companies define COVID-19 symptoms differently. They said that the efficacy rate of a vaccine should be evaluated in a more comprehensive manner, citing Sinovac as an example.
Sinovac vaccine received a 50.3-percent efficacy rate on Wednesday, based on phase III clinical trials in Brazil. But the figure was largely due to the fact that participants in Brazil are all medical workers with a very high infection risk, experts said.
Doshi on January 4 released an article on a blog platform under the UK pharmaceutical journal The BMJ, questioning Pfizer's efficacy rate.
Pfizer revealed that it discovered 170 PCR confirmed COVID-19 cases during the phase III clinical trials and 3,410 suspected cases in total.
However, if taking these suspected cases all as confirmed ones, the Pfizer vaccine's efficacy would be dramatically reduced to 19 percent. Even after omitting cases occurring within seven days of vaccination, which should include the majority of symptoms due to short-term vaccine reactogenicity, the efficacy rate remains as low as 29 percent, Doshi said in the article.
Doshi also questioned the standards of how Pfizer excluded cases and the influence of the use of medication on the vaccine's efficacy.
Doshi's comments triggered controversy on Chinese social media platforms, with some Chinese experts doubting Doshi's counting method for efficacy as he takes all participants showing symptoms to be confirmed COVID-19 cases, even if PRC tests show negative results.
"The PRC test is of very high sensitivity, 98.6 percent in the last year. But its sensitivity could be only 5 percent under Doshi's counting method," Zhuang Shilihe, a Guangzhou-based vaccine doctor, told the Global Times on Wednesday.
Zhuang noted that Doshi's doubts may be related to the anti-vaccine movement in the US, noting that Doshi has previously criticized other vaccines like the flu vaccines.
A Beijing-based vaccine expert who required anonymity expressed distrust of Pfizer's efficacy, but he did not directly comment on Doshi's doubts.
Despite different opinions on the Pfizer vaccine's efficacy, both experts said that Pfizer should reveal the raw data for peer review to better analyze the vaccine, so as to exclude the influence of any environmental or other elements on the efficacy.
- 注册
- 2007-08-08
- 消息
- 8,882
- 荣誉分数
- 1,408
- 声望点数
- 373
3,410 suspected cases假如都经过PCR test negative， 而且PCR又有98.6%的sensitivity， 可以认为Pfizer排除这3410个疑似病例是对的， 即使考虑误差，不到5%而已。
